Drug intelligence / Profile preview

GB241

Development stage: Phase 3
Lead developer: Genor Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GB241 is a biosimilar of rituximab developed by Genor Biopharma and Nanjing Yoko Biomedical. It is a recombinant chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes. The drug acts primarily through antibody-dependent cell cytotoxicity and T lymphocyte stimulation, leading to the depletion of CD20-positive B cells. Its main clinical development focus has been as a first-line therapy for diffuse large B-cell lymphoma (DLBCL), where it is evaluated in combination with CHOP chemotherapy as an alternative to rituximab plus CHOP[2][3][7]. The drug is administered intravenously.

Other names: Rituximab biosimilar (GB241)Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on GB241.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB241.

Explore the full profile